Secondary Logo

Journal Logo

The MATE survey

men's perceptions and attitudes towards menopause and their role in partners’ menopausal transition

Parish, Sharon J. MD1; Faubion, Stephanie S. MD2; Weinberg, Marc3; Bernick, Brian MD3; Mirkin, Sebastian MD3

doi: 10.1097/GME.0000000000001373
Original Study: PDF Only

Objective: The perceptions and attitudes of menopause shared by men are largely unknown. This analysis characterized men's awareness and their understanding of their partner's menopausal transition.

Methods: A 35-question, online survey was used to assess men's perceptions and attitudes toward menopause. Men were recruited from an online research marketplace and were eligible to participate if their female partners (45-64 years old) experienced ≥1 of the following symptoms: hot flashes, night sweats, sleepless nights, difficulty sleeping, low libido, mood swings, pain during sex, or vaginal dryness. Couples either lived together full time, or, if living separately, resided together regularly two or more times a week.

Results: Of the 1,356 surveys sent to eligible men, 450 (33%) were completed. Most men were between 50 and 69 years (80%), married and not separated (90%), and lived with their partner full time (97%). Men were aware of the symptoms regularly experienced by their partner, with difficulty sleeping (54%) and lack of energy (49%) being frequently identified; these symptoms were attributed to menopause (26%) and/or aging (22%). Of those who were affected by symptoms (63%), most men reported they negatively impacted them (77%), their partners (70%), and relationships (56%). Men engaged in discussions with their partners regarding menopausal symptoms (72%) and believed they were somewhat/very influential (75%) in their partner's decision to seek treatment or make lifestyle adjustments.

Conclusions: Overall, men are aware of their partner's menopausal transition and may influence decisions relating to symptom management. Educational interventions would further benefit men's awareness of menopause and available treatment options.

Video Summary:

This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

1Weill Cornell Medical College, New York, NY

2Women's Health Clinic, Division of General Internal Medicine, Mayo Clinic, Rochester, MN

3TherapeuticsMD, Boca Raton, FL.

Address correspondence to: Sharon J. Parish, MD, Weill Cornell Medicine, 21 Bloomingdale Road, White Plains, NY 10605. E-mail:

Received 31 January, 2019

Revised 9 April, 2019

Accepted 9 April, 2019

Data presentation: An oral presentation will be presented at the 2019 Annual Clinical and Scientific Meeting for ACOG on May 3-6, 2019, in Nashville, TN.

Funding/support: TherapeuticsMD (Boca Raton, FL).

Financial disclosure/conflicts of interest: This survey was funded by TherapeuticsMD (Boca Raton, FL). Dr Parish is on the advisory board of AMAG; serves as a consultant for Dare, JDS Therapeutics, Sprout, Strategic Scientific Technologies (SST), TherapeuticsMD, and Procter & Gamble; and has received writing support from AMAG and TherapeuticsMD. Dr Faubion consults for or is on the advisory board of AMAG, Mithra, and Procter & Gamble. Drs Bernick and Mirkin, and Mr Weinberg are employees of TherapeuticsMD with stock/stock options. Dr Bernick is also a Board member of TherapeuticsMD.

Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Website (

© 2019 by The North American Menopause Society.